Cerebrolysin Injection is a peptide-based therapy derived from porcine brain proteins that has been used for decades to support neuronal recovery and regeneration. The formulation contains low-molecular-weight peptides and amino acids that are believed to cross the blood‑brain barrier and exert neurotrophic effects. By stimulating nerve growth factors and protecting neurons from damage, this injection can help improve outcomes after strokes, traumatic brain injuries and neurodegenerative conditions such as Alzheimer’s disease or vascular dementia.
This treatment is typically administered by a healthcare professional via intravenous injection or infusion. Dosage depends on the patient’s age, weight and specific neurological condition; it often ranges from 5 ml to 30 ml daily for a period of several days or weeks. Because Cerebrolysin Injection must be given intravenously, patients should never self‑administer it. The therapy may be used alone or in conjunction with other rehabilitative interventions, such as physical therapy, cognitive exercises and lifestyle modifications. Early administration following a stroke or injury may improve functional recovery.
Common side effects can include headache, dizziness, agitation, sweating or injection site reactions. In some cases, allergic reactions, palpitations or confusion may occur; tell your doctor immediately if you notice any unusual symptoms. This therapy is generally well tolerated, but it should be avoided in patients with severe renal impairment, epilepsy, or hypersensitivity to peptide preparations. Pregnant or breastfeeding women and children should only receive it if clearly needed and under strict medical supervision. Because this treatment works best when part of a comprehensive care plan, it is essential to maintain regular follow‑ups with a neurologist, adhere to prescribed medications and engage in rehabilitation programs. A healthy lifestyle, including a balanced diet, adequate sleep, physical activity and cognitive stimulation, can complement neuroprotective therapies and support long-term brain health.
This treatment is typically administered by a healthcare professional via intravenous injection or infusion. Dosage depends on the patient’s age, weight and specific neurological condition; it often ranges from 5 ml to 30 ml daily for a period of several days or weeks. Because Cerebrolysin Injection must be given intravenously, patients should never self‑administer it. The therapy may be used alone or in conjunction with other rehabilitative interventions, such as physical therapy, cognitive exercises and lifestyle modifications. Early administration following a stroke or injury may improve functional recovery.
Common side effects can include headache, dizziness, agitation, sweating or injection site reactions. In some cases, allergic reactions, palpitations or confusion may occur; tell your doctor immediately if you notice any unusual symptoms. This therapy is generally well tolerated, but it should be avoided in patients with severe renal impairment, epilepsy, or hypersensitivity to peptide preparations. Pregnant or breastfeeding women and children should only receive it if clearly needed and under strict medical supervision. Because this treatment works best when part of a comprehensive care plan, it is essential to maintain regular follow‑ups with a neurologist, adhere to prescribed medications and engage in rehabilitation programs. A healthy lifestyle, including a balanced diet, adequate sleep, physical activity and cognitive stimulation, can complement neuroprotective therapies and support long-term brain health.
0